Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biol Neonate ; 64(2-3): 110-5, 1993.
Artículo en Inglés | MEDLINE | ID: mdl-8260542

RESUMEN

In a randomized prospective study in 116 selected neonates with very low birth weight, the effect of standard doses of intravenously administered immunoglobulins (IVIG) on the occurrence of severe infections was studied. No difference in infection rate or severity of infection could be observed between the treated neonates and the control group. The lack of effect could not be explained by an insufficient increase in the IgG serum levels, or inversely, by high immunosuppressive IgG levels. It is concluded that in very low birth weight neonates the administration of IVIG, under the conditions used in this investigation, does not protect against severe infection.


Asunto(s)
Inmunoglobulinas Intravenosas/uso terapéutico , Recién Nacido de Bajo Peso , Control de Infecciones/métodos , Femenino , Humanos , Inmunoglobulina G/sangre , Incidencia , Recién Nacido de Bajo Peso/sangre , Recién Nacido , Infecciones/epidemiología , Infecciones/microbiología , Masculino , Estudios Prospectivos , Valores de Referencia , Insuficiencia del Tratamiento
2.
Acta Clin Belg ; 48(1): 11-9, 1993.
Artículo en Holandés | MEDLINE | ID: mdl-8388600

RESUMEN

Estrogen treatment in high doses is effective in reducing adult stature in constitutionally tall girls. In this study, growth data of 38 normal girls with a predicted final height beyond 178 cm, are reported. They were treated with ethinyloestradiol in a daily dose of 0.200 mg until the epiphyseal plates were practically fused. In addition, medroxyprogesterone acetate at a dose of 10 mg daily was given for 5 to 12 days every month. The reduction of final height occurred with decreased growth velocity and accelerated epiphyseal closure. The major factor affecting the response to treatment was skeletal age. The lower the skeletal age, the greater the difference between the predicted final height and the final height. This gain was directly related to the growth potential at start of therapy. The best time to start treatment might be the pre-menarche period at a bone age of 12 years. Serious side-effects were not reported, but treatment should be employed only when height prediction is excessive.


Asunto(s)
Etinilestradiol/uso terapéutico , Trastornos del Crecimiento/tratamiento farmacológico , Adolescente , Estatura/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Niño , Quimioterapia Combinada , Etinilestradiol/administración & dosificación , Femenino , Humanos , Medroxiprogesterona/administración & dosificación , Menarquia/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA